Intellia Therapeutics (NASDAQ:NTLA) Given “Buy” Rating at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They presently have a $26.00 price target on the stock. Chardan Capital’s price target points to a potential upside of 82.07% from the company’s previous close.

Several other equities analysts have also issued reports on NTLA. Oppenheimer set a $27.00 target price on shares of Intellia Therapeutics in a report on Friday, November 7th. JonesTrading cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a report on Wednesday, November 12th. Evercore set a $8.00 target price on Intellia Therapeutics and gave the stock an “in-line” rating in a research note on Tuesday, November 11th. Finally, Royal Bank Of Canada lowered their price target on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.48.

Intellia Therapeutics Stock Up 6.4%

Shares of NTLA stock opened at $14.28 on Friday. The business’s fifty day moving average is $11.80 and its 200 day moving average is $13.00. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -3.34 and a beta of 2.10. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The firm had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same period in the prior year, the firm earned ($1.27) EPS. The company’s revenue was up 78.4% compared to the same quarter last year. Equities research analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 34,146 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at $907,488.93. This trade represents a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,051 shares of company stock worth $488,600 in the last 90 days. 3.10% of the stock is currently owned by insiders.

Institutional Trading of Intellia Therapeutics

A number of large investors have recently modified their holdings of NTLA. Oppenheimer & Co. Inc. lifted its holdings in Intellia Therapeutics by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after buying an additional 808 shares during the period. CWM LLC grew its position in Intellia Therapeutics by 4.7% during the 3rd quarter. CWM LLC now owns 19,187 shares of the company’s stock worth $331,000 after purchasing an additional 856 shares during the last quarter. Comerica Bank increased its holdings in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the period. Federated Hermes Inc. raised its stake in shares of Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after purchasing an additional 927 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC lifted its holdings in shares of Intellia Therapeutics by 9.3% during the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock worth $202,000 after purchasing an additional 995 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations — loss per share was smaller than expected and revenue nearly doubled year-over-year, signaling commercial/partner progress and giving the stock an immediate bullish trigger. Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: FDA lifted the clinical hold on MAGNITUDE‑2 and management laid out 2026 plans for lonvo‑z (HAE), including expected Phase 3 readout timing, BLA timing and a targeted U.S. launch window — this materially de‑risks a key commercial program. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Balance sheet strength — Intellia ended 2025 with roughly $605M in cash and marketable securities, which supports ongoing trials and commercial preparation into pivotal readouts. Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Neutral Sentiment: Analyst model updates from Brookline Capital show continued 2026 quarterly losses (multiple quarters forecast negative EPS), but the firm materially increased FY2028/FY2029 earnings projections — signaling high conviction in longer‑term commercial upside despite short‑term losses.
• Negative Sentiment: Company remains loss‑making with a negative net margin and negative ROE; consensus still expects a large full‑year 2026 loss (around -$5.07 EPS), which leaves the stock sensitive to execution and cash‑burn news. Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Regulatory risk is not fully cleared — while MAGNITUDE‑2 hold was lifted, engagement is ongoing to resolve a hold on another MAGNITUDE trial (ATTR‑CM), keeping upside contingent on additional FDA interactions and successful re‑starts. Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (Yahoo)

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.